Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 11, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not provide company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data present relates to specific share transactions:
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Transaction Price: £15.6364 per share.
- Transaction Volume: 16 Ordinary Shares per executive (comprising 8 partnership shares and 8 matching shares).
- Transaction Date: July 10, 2018.
- Exchange: London Stock Exchange (XLON).
Material Changes
The filing does not report material changes to the company's financial position or operations. It solely documents routine acquisitions of shares under the Company's Share Reward Plan by nine senior executives on a single date.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific equity transactions.
Investor Verification Points
- Verify the total number of shares acquired by the nine listed executives (Ms E Walmsley, Mr R G Connor, Mr S Dingemans, Mr N Hirons, Mr L Miels, Mr D S Redfern, Ms C Thomas, Mr P C Thomson, and Mrs V A Whyte).
- Confirm the transaction price of £15.6364 aligns with the market price on July 10, 2018.
- Note that all transactions were acquisitions under the Share Reward Plan, indicating no open-market sales by these executives on this date.